Serological Biomarker-Based Machine Learning Models for Predicting the Relapse of Ulcerative Colitis
Wenwen Pang,Bowei Zhang,Leixin Jin,Yao Yao,Qiurong Han,Xiaoli Zheng
DOI: https://doi.org/10.2147/JIR.S423086
IF: 4.5
2023-08-22
Journal of Inflammation Research
Abstract:Wenwen Pang, 1, &ast Bowei Zhang, 2, &ast Leixin Jin, 3 Yao Yao, 3 Qiurong Han, 3 Xiaoli Zheng 1 1 Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University, Tianjin, People's Republic of China; 2 School of Medicine, Nankai University, Tianjin, People's Republic of China; 3 School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoli Zheng, 190 Huayuan Road, Tianjin, People's Republic of China, Tel +86 13612135765, Fax +022 87729595, Email Purpose: To explore whether machine learning models using serological markers can predict the relapse of Ulcerative colitis (UC). Patients and Methods: This clinical cohort study included 292 UC patients, and serological markers were obtained when patients were discharged from the hospital. Subsequently, four machine learning models including the random forest (RF) model, the logistic regression model, the decision tree, and the neural network were compared to predict the relapse of UC. A nomogram was constructed, and the performance of these models was evaluated by accuracy, sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC). Results: Based on the patients' characteristics and serological markers, we selected the relevant variables associated with relapse and developed a LR model. The novel model including gender, white blood cell count, percentage of leukomonocyte, percentage of monocyte, absolute value of neutrophilic granulocyte, and erythrocyte sedimentation rate was established for predicting the relapse. In addition, the average AUC of the four machine learning models was 0.828, of which the RF model was the best. The AUC of the test group was 0.889, the accuracy was 76.4%, the sensitivity was 78.5%, and the specificity was 76.4%. There were 45 variables in the RF models, and the relative weight coefficients of these variables were determined. Age has the greatest impact on classification results, followed by hemoglobin concentration, white blood cell count, and platelet distribution width. Conclusion: Machine learning models based on serological markers had high accuracy in predicting the relapse of UC. The model can be used to noninvasively predict patient outcomes and can be an effective tool for determining personalized treatment plans. Keywords: ulcerative colitis, relapse, serological markers, machine learning, random forest model Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa, and its incidence is rising worldwide. 1 It starts in the rectum and extends proximally to part or the entire colon in a continuous manner. 2 UC usually presents with bloody diarrhea and the aim of management is to induce and maintain remission, defined as relief of symptoms and endoscopic healing. 3 The diagnosis of UC is based on symptoms, endoscopic findings, and other alternative diagnoses. Endoscopy is the gold standard test for evaluating UC activity and healing, but it is an expensive, invasive, and uncomfortable procedure for patients. Diagnostic modalities need to be improved for more rigorous monitoring of disease activity. UC has evolved into a global burden given its high rate of relapse, which requires a two-pronged solution that includes research on interventions to prevent UC and innovation in providing care for UC patients. Treatment for UC patients includes 5-aminosalicylic acids (5-ASA), steroids, and immunosuppressants. Patients might have anemia, iron deficiency, leucocytosis, or thrombocytosis. Hypoalbuminaemia may be a predictor of colectomy and adverse reactions to biological drugs. 4 Some biomarkers of inflammation, such as erythrocyte sedimentation rate (ESR) and C-reactive protein, can be elevated (severe UC) or normal (mild to moderate disease). 5 The course of clinical relapse of UC is difficult to predict. Strict and effective management is the key to improving the prognosis of UC patients. 6 Therefore, it is urgent to accurately predict UC relapse. The diagnostic armamentarium for ulcerative colitis is expanding, and the serological markers have become a focus for the diagnosis and prognosis of UC because they are convenient, non-invasive, and relatively inexpensive compared to other markers in biopsy tissue or stool. 7 Classical serological markers, such as perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCAs), are initially used for diagnostic purposes, and later used to predict the -Abstract Truncated-
immunology